M
Meg Watson
Researcher at Centers for Disease Control and Prevention
Publications - 77
Citations - 6726
Meg Watson is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 34, co-authored 74 publications receiving 5701 citations. Previous affiliations of Meg Watson include American Society for Clinical Pathology & University of Kentucky.
Papers
More filters
Journal ArticleDOI
Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels
Ahmedin Jemal,Edgar P. Simard,Christina G. Dorell,Anne-Michelle Noone,Lauri E. Markowitz,Betsy A. Kohler,Christie R. Eheman,Mona Saraiya,Priti Bandi,Debbie Saslow,Kathleen A. Cronin,Meg Watson,Mark Schiffman,S. Jane Henley,Maria J. Schymura,Robert N. Anderson,David Yankey,Brenda K. Edwards +17 more
TL;DR: The overall trends in declining cancer death rates continue, however, increases in incidence rates for some HPV-associated cancers and low vaccination coverage among adolescents underscore the need for additional prevention efforts for HPV- associated cancers, including efforts to increase vaccination coverage.
Journal ArticleDOI
Barriers to Human Papillomavirus Vaccination Among US Adolescents: A Systematic Review of the Literature
TL;DR: A systematic review of the literature on barriers to HPV vaccination among US adolescents to inform future efforts to increase HPV vaccine coverage was conducted by as mentioned in this paper, where 55 relevant articles were summarized by target populations: health care professionals, parents, underserved and disadvantaged populations, and males.
Journal ArticleDOI
Human Papillomavirus-Associated Cancers - United States, 2008-2012.
Laura Viens,S. Jane Henley,Meg Watson,Lauri E. Markowitz,Cheryll C. Thomas,Trevor D. Thompson,Hilda Razzaghi,Mona Saraiya +7 more
TL;DR: To assess the incidence of HPV-associated cancers, CDC analyzed 2008-2012 high-quality data from the CDC's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology, and End Results program.
Journal ArticleDOI
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Mona Saraiya,Elizabeth R. Unger,Trevor D. Thompson,Charles F. Lynch,Brenda Y. Hernandez,Christopher Lyu,Martin Steinau,Meg Watson,Edward J. Wilkinson,Claudia Hopenhayn,Glenn Copeland,Wendy Cozen,Edward S. Peters,Youjie Huang,Maria Sibug Saber,Sean F. Altekruse,Marc T. Goodman +16 more
TL;DR: In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine.
Journal Article
Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030.
Gery P. Guy,Cheryll C. Thomas,Trevor D. Thompson,Meg Watson,Greta M. Massetti,Lisa C. Richardson +5 more
TL;DR: The number of melanoma cases is projected to increase over the next 15 years, with accompanying increases in health care costs, and much of this morbidity, mortality, and health care cost can be prevented.